Literature DB >> 15733021

Disease-modifying therapies for osteoarthritis : current status.

Marc Fajardo1, Paul E Di Cesare.   

Abstract

Osteoarthritis, the most common form of arthritis, is a debilitating progressive disease principally affecting the elderly. Osteoarthritis therapy has evolved in the past few decades from symptomatic treatment to possible disease-modifying solutions. In this paper, the pathophysiology of osteoarthritis is first reviewed, including an examination of the mechanisms underlying osteoarthritis and discussions of the roles of cartilage, synovial fluid and subchondral bone. The remainder of the paper discusses therapeutic approaches in current use and those in development, with special attention given to pharmacological treatments. Current approaches to treating osteoarthritis--i.e. medications; nonpharmacological modalities, such as physical therapy, exercise, weight management and orthotics; and (as a last resort) surgery--focus on reducing pain and improving (or at least maintaining) mobility. Drugs currently used to treat osteoarthritis fall into several categories: analgesics, NSAIDs, cyclo-oxygenase-2 (COX-2) inhibitors, corticosteroids, viscosupplementation, and symptomatic slow-acting drugs ('nutraceuticals'). The analgesics (paracetamol [acetaminophen] and opiates) have demonstrated less symptomatic efficacy than NSAIDs, while the latter have displayed mixed results in terms of joint space narrowing. COX-2 inhibitors have been demonstrated to be equal to or superior to NSAIDs in effectiveness. However, once considered a safer alternative, COX-2 inhibitors have become the subject of intense scrutiny since recent clinical evidence has cast suspicion on their cardiovascular safety profile. Injectable therapies, such as corticosteroids and viscosupplementation have elicited favorable short-term response but no long-term structural modification. On the other hand, the slow-acting drugs, especially chondroitin and glucosamine sulfate, have shown promising results. Also reviewed are other established and experimental therapies that seek to modify and/or even reverse the course of osteoarthritis. These include such medications as colchicine, bisphosphonates and hormones; dietary therapeutics, such as ginger extract and green tea; and such truly experimental treatments as matrix metalloproteinase inhibitors, cytokines, nitric oxide, growth factors and gene therapy. Osteoarthritis continues to be a difficult disorder to treat, as there is no cure as such and current treatments focus mainly on relieving pain and maintaining joint function. The search nevertheless continues for management regimens that can slow, alter or reverse the degenerative processes of osteoarthritis.

Entities:  

Mesh:

Year:  2005        PMID: 15733021     DOI: 10.2165/00002512-200522020-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  116 in total

Review 1.  Perspectives on the Women's Health Initiative trial of hormone replacement therapy.

Authors:  David A Grimes; Rogerio A Lobo
Journal:  Obstet Gynecol       Date:  2002-12       Impact factor: 7.661

2.  Nitric oxide attenuates cellular hexose monophosphate shunt response to oxidants in articular chondrocytes and acts to promote oxidant injury.

Authors:  R M Clancy; S B Abramson; C Kohne; J Rediske
Journal:  J Cell Physiol       Date:  1997-08       Impact factor: 6.384

Review 3.  Intra-articular therapy in osteoarthritis.

Authors:  J R Kirwan; E Rankin
Journal:  Baillieres Clin Rheumatol       Date:  1997-11

Review 4.  Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases.

Authors:  P Borden; R A Heller
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1997       Impact factor: 1.807

5.  Effects of a ginger extract on knee pain in patients with osteoarthritis.

Authors:  R D Altman; K C Marcussen
Journal:  Arthritis Rheum       Date:  2001-11

6.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.

Authors:  J D Bradley; K D Brandt; B P Katz; L A Kalasinski; S I Ryan
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

7.  Lubrication of animal joints. 3. The effect of certain chemical alterations of the cartilage and lubricant.

Authors:  F C Linn; E L Radin
Journal:  Arthritis Rheum       Date:  1968-10

Review 8.  Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate.

Authors:  C L Deal; R W Moskowitz
Journal:  Rheum Dis Clin North Am       Date:  1999-05       Impact factor: 2.670

9.  Intra-articular sodium hyaluronate in osteoarthritis of the knee: a multicenter, double-blind study.

Authors:  W Puhl; A Bernau; H Greiling; W Köpcke; W Pförringer; K J Steck; J Zacher; H P Scharf
Journal:  Osteoarthritis Cartilage       Date:  1993-10       Impact factor: 6.576

10.  Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group.

Authors:  J P Pelletier; M Yaron; B Haraoui; P Cohen; M A Nahir; D Choquette; I Wigler; I A Rosner; A D Beaulieu
Journal:  Arthritis Rheum       Date:  2000-10
View more
  23 in total

1.  Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).

Authors:  Yun Ding; Heather O'Keefe; Jennifer L DeLorey; David I Israel; Jeffrey A Messer; Cynthia H Chiu; Steven R Skinner; Rosalie E Matico; Monique F Murray-Thompson; Fan Li; Matthew A Clark; John W Cuozzo; Christopher Arico-Muendel; Barry A Morgan
Journal:  ACS Med Chem Lett       Date:  2015-07-07       Impact factor: 4.345

Review 2.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 3.  Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues.

Authors:  Benjamin G Cooper; Ara Nazarian; Brian D Snyder; Mark W Grinstaff
Journal:  Biomaterials       Date:  2018-07-26       Impact factor: 12.479

Review 4.  Chondroitin for osteoarthritis.

Authors:  Jasvinder A Singh; Shahrzad Noorbaloochi; Roderick MacDonald; Lara J Maxwell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-28

5.  Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis: a randomized controlled non-inferiority trial.

Authors:  Rong Mu; Chun-de Bao; Zhi-wei Chen; Yi Zheng; Guo-chun Wang; Dong-bao Zhao; Shao-xian Hu; Yu-jun Li; Zeng-wu Shao; Zhi-yi Zhang; Wei-guo Xiao; Weiya Zhang; Zhan-guo Li
Journal:  Clin Rheumatol       Date:  2014-06-14       Impact factor: 2.980

6.  Posttraumatic knee osteoarthritis following anterior cruciate ligament injury: Potential biochemical mediators of degenerative alteration and specific biochemical markers.

Authors:  Hong Li; Chen Chen; Shiyi Chen
Journal:  Biomed Rep       Date:  2014-12-17

7.  A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis.

Authors:  Stephen P Myers; Joan O'Connor; J Helen Fitton; Lyndon Brooks; Margaret Rolfe; Paul Connellan; Hans Wohlmuth; Phil A Cheras; Carol Morris
Journal:  Biologics       Date:  2010-03-24

8.  Comparison of safety, efficacy and tolerability of dexibuprofen and ibuprofen in the treatment of osteoarthritis of the hip or knee.

Authors:  Omid Zamani; Elke Böttcher; Jörg D Rieger; Johann Mitterhuber; Reinhold Hawel; Sylvia Stallinger; Norbert Eller
Journal:  Wien Klin Wochenschr       Date:  2014-04-17       Impact factor: 1.704

9.  Short term results comparison of intraarticular platelet-rich plasma (prp) and hyaluronic acid (ha) applications in early stage of knee osteoarthritis.

Authors:  Volkan Kilincoglu; Abdurrahman Yeter; Erkan Servet; Mustafa Kangal; Mustafa Yildirim
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 10.  Detection of calcium phosphate crystals in the joint fluid of patients with osteoarthritis - analytical approaches and challenges.

Authors:  Alexander Yavorskyy; Aaron Hernandez-Santana; Geraldine McCarthy; Gillian McMahon
Journal:  Analyst       Date:  2008-02-01       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.